Fungus as the cause of chronic rhinosinusitis: The case remains unproven

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 17, Issue 1, 2009, Pages 43-49

  Ebbens, Fenna A ^a   Georgalas, Christos ^a   Fokkens, Wytske J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Allergic fungal sinusitis; Antifungals; Chronic rhinosinusitis; Fungi; Immunotherapy; Nasal polyps; Pathogenesis

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; DEFENSIN; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT; INTERLEUKIN 13; INTERLEUKIN 5; KETOCONAZOLE; LACTOFERRIN; LYSOZYME; PLACEBO; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C; SURFACTANT PROTEIN D; TERBINAFINE;

ALLERGIC FUNGAL SINUSITIS; ALTERNARIA; ASPERGILLUS; CHRONIC RHINOSINUSITIS; CLADOSPORIUM; CYTOKINE PRODUCTION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EOSINOPHIL; FUNGAL DETECTION; FUNGUS; FUNGUS CULTURE; HOST RESISTANCE; HUMAN; HYPERSENSITIVITY REACTION; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MYCOSIS; NONHUMAN; PATHOGENESIS; PENICILLIUM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RHINOSINUSITIS; SINUSITIS; STAINING; TREATMENT DURATION; TREATMENT OUTCOME; CHRONIC DISEASE; FEMALE; FOLLOW UP; HOSPITALIZATION; IMMUNOLOGY; MALE; MICROBIOLOGY; NOSE MUCOSA; PARANASAL SINUS; PERENNIAL RHINITIS; RHINITIS; RISK ASSESSMENT;

ANTIFUNGAL AGENTS; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MYCOSES; NASAL MUCOSA; PARANASAL SINUSES; RHINITIS; RHINITIS, ALLERGIC, PERENNIAL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SINUSITIS; TREATMENT OUTCOME;

EID: 66149131520     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOO.0b013e32831de91e     Document Type: Review

References (69)

1. Fokkens W, Lund V, Mullol J. European position paper on rhinosinusitis and nasal polyps 2007. Rhinol Suppl 2007; 20:1-136. Important evidence-based position paper on the pathophysiology and management of CRS.
2. Fokkens W, Lund V, Mullol J. EP3OS 2007: European position paper on rhinosinusitis and nasal polyps 2007. A summary for otorhinolaryngologists. Rhinology 2007; 45:97-101.
3. Katzenstein AL, Sale SR, Greenberger PA. Allergic Aspergillus sinusitis: a newly recognized form of sinusitis. J Allergy Clin Immunol 1983; 72:89-93.
4. Robson JM, Hogan PG, Benn RA, Gatenby PA. Allergic fungal sinusitis presenting as a paranasal sinus tumour. Aust N Z J Med 1989; 19:351-353.
5. Bent JP III, Kuhn FA. Diagnosis of allergic fungal sinusitis. Otolaryngol Head Neck Surg 1994; 111:580-588.
6. deShazo RD, Swain RE. Diagnostic criteria for allergic fungal sinusitis. J Allergy Clin Immunol 1995; 96:24-35.
7. Ponikau JU, Sherris DA, Kern EB, et al. The diagnosis and incidence of allergic fungal sinusitis. Mayo Clin Proc 1999; 74:877-884. (Pubitemid 29430354)
8. Catten MD, Murr AH, Goldstein JA, et al. Detection of fungi in the nasal mucosa using polymerase chain reaction. Laryngoscope 2001; 111:399-403. (Pubitemid 32200079)
9. Rao AK, Mathers PH, Ramadan HH. Detection of fungi in the sinus mucosa using polymerase chain reaction. Otolaryngol Head Neck Surg 2006; 134:581-585.
10. Polzehl D, Weschta M, Podbielski A, et al. Fungus culture and PCR in nasal lavage samples of patients with chronic rhinosinusitis. J Med Microbiol 2005; 54:31-37.
11. Scheuller MC, Murr AH, Goldberg AN, et al. Quantitative analysis of fungal DNA in chronic rhinosinusitis. Laryngoscope 2004; 114:467-471. (Pubitemid 38391910)
12. Kim ST, Choi JH, Jeon HG, et al. Comparison between polymerase chain reaction and fungal culture for the detection of fungi in patients with chronic sinusitis and normal controls. Acta Otolaryngol 2005; 125:72-75.
13. Murr AH, Goldberg AN, Vesper S. Fungal speciation using quantitative polymerase chain reaction (QPCR) in patients with and without chronic rhinosinusitis. Laryngoscope 2006; 116:1342-1348. (Pubitemid 44181444)
14. Weschta M, Rimek D, Formanek M, et al. Topical antifungal treatment of chronic rhinosinusitis with nasal polyps: a randomized, double-blind clinical trial. J Allergy Clin Immunol 2004; 113:1122-1128. (Pubitemid 38857995)
15. Taylor MJ, Ponikau JU, Sherris DA, et al. Detection of fungal organisms in eosinophilic mucin using a fluorescein-labeled chitin-specific binding protein. Otolaryngol Head Neck Surg 2002; 127:377-383.
16. Kennedy DW, Kuhn FA, Hamilos DL, et al. Treatment of chronic rhinosinusitis with high-dose oral terbinafine: a double blind, placebo-controlled study. Laryngoscope 2005; 115:1793-1799.
17. Buzina W, Braun H, Freudenschuss K, et al. Fungal biodiversity - as found in nasal mucus. Med Mycol 2003; 41:149-161. (Pubitemid 41001693)
18. Ponikau JU, Sherris DA, Weaver A, Kita H. Treatment of chronic rhinosinusitis with intranasal amphotericin B: a randomized, placebo-controlled, doubleblind pilot trial. J Allergy Clin Immunol 2005; 115:125-131. (Pubitemid 40075432)
19. Jiang RS, Su MC, Lin JF. Nasal mycology of chronic rhinosinusitis. Am J Rhinol 2005; 19:131-133.
20. Hafidh M, Harney M, Kane R, et al. The role of fungi in the etiology of chronic rhinosinusitis: a prospective study. Auris Nasus Larynx 2007; 34:185-189. (Pubitemid 46603204)
21. Tosun F, Hidir Y, Saracli MA, et al. Intranasal fungi and chronic rhinosinusitis: what is the relationship? Ann Otol Rhinol Laryngol 2007; 116:425-429.
22. Aydil U, Kalkanci A, Ceylan A, et al. Investigation of fungi in massive nasal polyps: microscopy, culture, polymerase-chain reaction, and serology. Am J Rhinol 2007; 21:417-422. (Pubitemid 47360027)
23. Liang KL, Su MC, Shiao JY, et al. Amphotericin B irrigation for the treatment of chronic rhinosinusitis without nasal polyps: a randomized, placebo-controlled, double-blind study. Am J Rhinol 2008; 22:52-58. Third double-blind placebo-controlled trial showing no efficacy of topical amphotericin B in patients with CRS.
24. Kostamo K, Richardson M, Virolainen-Julkunen A, et al. Microbiology of chronic hyperplastic sinusitis. Rhinology 2004; 42:213-218.
25. Granville L, Chirala M, Cernoch P, et al. Fungal sinusitis: histologic spectrum and correlation with culture. Hum Pathol 2004; 35:474-481. (Pubitemid 38507085)
26. Gosepath J, Brieger J, Vlachtsis K, Mann WJ. Fungal DNA is present in tissue specimens of patients with chronic rhinosinusitis. Am J Rhinol 2004; 18:9-13. (Pubitemid 38351408)
27. Braun H, Buzina W, Freudenschuss K, et al. 'Eosinophilic fungal rhinosinusitis': a common disorder in Europe? Laryngoscope 2003; 113:264-269.
28. Corradini C, Del NM, Buonomo A, et al. Amphotericin B and lysine acetylsalicylate in the combined treatment of nasal polyposis associated with mycotic infection. J Investig Allergol Clin Immunol 2006; 16:188-193. (Pubitemid 43911061)
29. Ebbens FA, Georgalas C, Rinia AB, et al. The fungal debate: where do we stand today? Rhinology 2007; 45:178-189.
30. Ponikau JU, Sherris DA, Kita H, Kern EB. Intranasal antifungal treatment in 51 patients with chronic rhinosinusitis. J Allergy Clin Immunol 2002; 110:862-866. (Pubitemid 36005872)
31. Ebbens FA, Scadding GK, Badia L, et al. Amphotericin B nasal lavages: not a solution for patients with chronic rhinosinusitis. J Allergy Clin Immunol 2006; 118:1149-1156. (Pubitemid 44666994)
32. Pant H, Kette FE, Smith WB, et al. Fungal-specific humoral response in eosinophilic mucus chronic rhinosinusitis. Laryngoscope 2005; 115:601-606. (Pubitemid 40530007)
33. Shin SH, Ponikau JU, Sherris DA, et al. Chronic rhinosinusitis: an enhanced immune response to ubiquitous airborne fungi. J Allergy Clin Immunol 2004; 114:1369-1375. (Pubitemid 39575892)
34. Vroling AB, Fokkens WJ, van Drunen CM. How epithelial cells detect danger: aiding the immune response. Allergy 2008; 63:1110-1123.
35. Liote H, Zahm JM, Pierrot D, Puchelle E. Role of mucus and cilia in nasal mucociliary clearance in healthy subjects. Am Rev Respir Dis 1989; 140:132-136. (Pubitemid 19177093)
36. Kaliner MA. Human nasal host defense and sinusitis. J Allergy Clin Immunol 1992; 90:424-430.
37. Ganz T. Antimicrobial polypeptides. J Leukoc Biol 2004; 75:34-38.
38. Ponikau JU, Sherris DA, Kephart GM, et al. Features of airway remodeling and eosinophilic inflammation in chronic rhinosinusitis: is the histopathology similar to asthma? J Allergy Clin Immunol 2003; 112:877-882.
39. Ponikau JU, Sherris DA, Kephart GM, et al. Striking deposition of toxic eosinophil major basic protein in mucus: implications for chronic rhinosinusitis. J Allergy Clin Immunol 2005; 116:362-369.
40. Wei JL, Kita H, Sherris DA, et al. The chemotactic behavior of eosinophils in patients with chronic rhinosinusitis. Laryngoscope 2003; 113:303-306. (Pubitemid 36176998)
41. Griffin E, Hakansson L, Formgren H, et al. Increased chemokinetic and chemotactic responses of eosinophils in asthmatic patients. Allergy 1991; 46:255-265.
42. Koenderman L, van der BT, Schweizer RC, et al. Eosinophil priming by cytokines: from cellular signal to in vivo modulation. Eur Respir J Suppl 1996; 22:119s-125s. (Pubitemid 26271208)
43. Rainbird MA, Macmillan D, Meeusen EN. Eosinophil-mediated killing of Haemonchus contortus larvae: effect of eosinophil activation and role of antibody, complement and interleukin-5. Parasite Immunol 1998; 20:93-103. (Pubitemid 28179129)
44. Borish LC, Steinke JW. Cytokines and chemokines. J Allergy Clin Immunol 2003; 111:S460-S475.
45. Haselden BM, Syrigou E, Jones M, et al. Proliferation and release of IL-5 and IFN-gamma by peripheral blood mononuclear cells from cat-allergic asthmatics and rhinitics, noncat-allergic asthmatics, and normal controls to peptides derived from Fel d 1 chain 1. J Allergy Clin Immunol 2001; 108:349-356. (Pubitemid 32881054)
46. Douglas R, Bruhn M, Tan LW, et al. Response of peripheral blood lymphocytes to fungal extracts and staphylococcal superantigen B in chronic rhinosinusitis. Laryngoscope 2007; 117:411-414. (Pubitemid 46407746)
47. Ooi EH, Wormald PJ, Carney AS, et al. Fungal allergens induce cathelicidin LL-37 expression in chronic rhinosinusitis patients in a nasal explant model. Am J Rhinol 2007; 21:367-372. Decreased levels of antimicrobial peptides () may be involved in CRS pathogenesis.
48. Cole AM, Liao HI, Stuchlik O, et al. Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol 2002; 169:6985-6991. (Pubitemid 36899286)
49. Fukami M, Stierna P, Veress B, Carlsoo B. Lysozyme and lactoferrin in human maxillary sinus mucosa during chronic sinusitis. An immunohistochemical study. Eur Arch Otorhinolaryngol 1993; 250:133-139.
50. Cavestro GM, Ingegnoli AV, Aragona G, et al. Lactoferrin: mechanism of action, clinical significance and therapeutic relevance. Acta Biomed 2002; 73:71-73. (Pubitemid 36245392)
51. Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A component of innate immunity prevents bacterial biofilm development. Nature 2002; 417:552-555.
52. Healy DY, Leid JG, Sanderson AR, Hunsaker DH. Biofilms with fungi in chronic rhinosinusitis. Otolaryngol Head Neck Surg 2008; 138:641-647.
53. Psaltis AJ, Bruhn MA, Ooi EH, et al. Nasal mucosa expression of lactoferrin in patients with chronic rhinosinusitis. Laryngoscope 2007; 117:2030-2035. Decreased levels of antimicrobial peptides (lactoferrin) may be involved in CRS pathogenesis.
54. Psaltis AJ,Wormald PJ, Ha KR, TanLW. Reduced levels of lactoferrin in biofilmassociated chronic rhinosinusitis. Laryngoscope 2008; 118:895-901.
55. Crouch E, Hartshorn K, Ofek I. Collectins and pulmonary innate immunity. Immunol Rev 2000; 173:52-65.
56. Ooi EH, Wormald PJ, Carney AS, et al. Surfactant protein D expression in chronic rhinosinusitis patients and immune responses in vitro to Aspergillus and Alternaria in a nasal explant model. Laryngoscope 2007; 117:51-57. Absence of surfactant protein-D may result in a reduced clearance of fungi from the nose and paranasal sinuses.
57. Kauffman HF, Tomee JF, van de Riet MA, et al. Protease-dependent activation of epithelial cells by fungal allergens leads to morphologic changes and cytokine production. J Allergy Clin Immunol 2000; 105:1185-1193.
58. Reed CE, Kita H. The role of protease activation of inflammation in allergic respiratory diseases. J Allergy Clin Immunol 2004; 114:997-1008. (Pubitemid 39469133)
59. Yoon J, Ponikau JU, Lawrence CB, Kita H. Innate antifungal immunity of human eosinophils mediated by a beta2 integrin, CD11b. J Immunol 2008; 181: 2907-2915.
60. Inoue Y, Matsuwaki Y, Shin SH, et al. Nonpathogenic, environmental fungi induce activation and degranulation of human eosinophils. J Immunol 2005; 175:5439-5447. (Pubitemid 41456430)
61. Bent JP III, Kuhn FA. Antifungal activity against allergic fungal sinusitis organisms. Laryngoscope 1996; 106:1331-1334. (Pubitemid 26374350)
62. Kfoury AG, Smith JC, Farhoud HH, et al. Adjuvant intrapleural amphotericin B therapy for pulmonary mucormycosis in a cardiac allograft recipient. Clin Transplant 1997; 11:608-612.
63. Leu HS, Huang CT. Clearance of funguria with short-course antifungal regimens: a prospective, randomized, controlled study. Clin Infect Dis 1995; 20:1152-1157.
64. Ricchetti A, Landis BN, Maffioli A, et al. Effect of antifungal nasal lavage with amphotericin B on nasal polyposis. J Laryngol Otol 2002; 116:261-263. (Pubitemid 34270836)
65. Helbling A, Baumann A, Hanni C, Caversaccio M. Amphotericin B nasal spray has no effect on nasal polyps. J Laryngol Otol 2006; 120:1023-1025. (Pubitemid 46132584)
66. Shirazi MA, Stankiewicz JA, Kammeyer P. Activity of nasal amphotericin B irrigation against fungal organisms in vitro. Am J Rhinol 2007; 21:145-148. (Pubitemid 46846341)
67. Rains BM III, Mineck CW. Treatment of allergic fungal sinusitis with high-dose itraconazole. Am J Rhinol 2003; 17:1-8. (Pubitemid 36395380)
68. Mabry RL, Marple BF, Folker RJ, Mabry CS. Immunotherapy for allergic fungal sinusitis: three years' experience. Otolaryngol Head Neck Surg 1998; 119: 648-651. (Pubitemid 29005489)
69. Mabry RL, Marple BF, Mabry CS. Outcomes after discontinuing immunotherapy for allergic fungal sinusitis. Otolaryngol Head Neck Surg 2000; 122:104-106. (Pubitemid 30051699)